Hepatic (Liver) Metastasis - Pipeline Review, H2 2014

Published: Nov, 2014 | Pages: 58 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Hepatic (Liver) Metastasis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Hepatic (Liver) Metastasis - Pipeline Review, H2 2014', provides an overview of the Hepatic (Liver) Metastasis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hepatic (Liver) Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatic (Liver) Metastasis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hepatic (Liver) Metastasis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Hepatic (Liver) Metastasis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Hepatic (Liver) Metastasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hepatic (Liver) Metastasis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hepatic (Liver) Metastasis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hepatic (Liver) Metastasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Hepatic (Liver) Metastasis Overview 7
Therapeutics Development 8
Pipeline Products for Hepatic (Liver) Metastasis - Overview 8
Pipeline Products for Hepatic (Liver) Metastasis - Comparative Analysis 9
Hepatic (Liver) Metastasis - Therapeutics under Development by Companies 10
Hepatic (Liver) Metastasis - Therapeutics under Investigation by Universities/Institutes 11
Hepatic (Liver) Metastasis - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Hepatic (Liver) Metastasis - Products under Development by Companies 14
Hepatic (Liver) Metastasis - Products under Investigation by Universities/Institutes 15
Hepatic (Liver) Metastasis - Companies Involved in Therapeutics Development 16
CytRx Corporation 16
Digna Biotech, S.L. 17
Gradalis Inc. 18
Incuron, LLC 19
Novartis AG 20
Phosplatin Therapeutics 21
TARGETOME 22
Hepatic (Liver) Metastasis - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
Antibodies to Inhibit FRMD4A for Oncology - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Cell Therapy to Target CEA for Oncology - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Cyt-HiPoA - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
DB-02901 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
mepacrine - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Monoclonal Antibody Conjugated to Activate p53 for Hepatic Metastasis - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
pasireotide - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
PT-112 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Recombinant Protein to Antagonize IGF-1R for Liver Metastasis and Breast Cancer - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
TGM-002 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
TGM-003 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Vaccine for cancer - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Hepatic (Liver) Metastasis - Recent Pipeline Updates 48
Hepatic (Liver) Metastasis - Dormant Projects 53
Hepatic (Liver) Metastasis - Discontinued Products 54
Hepatic (Liver) Metastasis - Product Development Milestones 55
Featured News & Press Releases 55
Apr 16, 2014: Cleveland BioLabs Announces the Successful Completion of a Phase 1 Study of CBL0102 55
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 58
Disclaimer 58

List of Tables
Number of Products under Development for Hepatic (Liver) Metastasis, H2 2014 8
Number of Products under Development for Hepatic (Liver) Metastasis - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Number of Products under Investigation by Universities/Institutes, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Hepatic (Liver) Metastasis - Pipeline by CytRx Corporation, H2 2014 16
Hepatic (Liver) Metastasis - Pipeline by Digna Biotech, S.L., H2 2014 17
Hepatic (Liver) Metastasis - Pipeline by Gradalis Inc., H2 2014 18
Hepatic (Liver) Metastasis - Pipeline by Incuron, LLC, H2 2014 19
Hepatic (Liver) Metastasis - Pipeline by Novartis AG, H2 2014 20
Hepatic (Liver) Metastasis - Pipeline by Phosplatin Therapeutics, H2 2014 21
Hepatic (Liver) Metastasis - Pipeline by TARGETOME, H2 2014 22
Assessment by Monotherapy Products, H2 2014 23
Number of Products by Stage and Target, H2 2014 25
Number of Products by Stage and Mechanism of Action, H2 2014 27
Number of Products by Stage and Route of Administration, H2 2014 29
Number of Products by Stage and Molecule Type, H2 2014 31
Hepatic (Liver) Metastasis Therapeutics - Recent Pipeline Updates, H2 2014 48
Hepatic (Liver) Metastasis - Dormant Projects, H2 2014 53
Hepatic (Liver) Metastasis - Discontinued Products, H2 2014 54